02389.HK

Oct 26, 2026, 11:01 UTC

Luo Xin Pharma said its board approved a plan to reduce the capital of four subsidiaries: Shanghai Luoxin by RMB 250 million, Hong Kong Luoxin by HKD 351 million (about RMB 301 million), Beijing Health (Holdings) Ltd. by RMB 224 million, and Hunan Health by RMB 90 million.